MedPath

Tasimelteon

TASIMELTEON capsules, for oral use

Approved
Approval ID

99cb1928-e57d-4d04-87a1-38108780598a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 24, 2023

Manufacturers
FDA

Amneal Pharmaceuticals NY LLC

DUNS: 123797875

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Tasimelteon

PRODUCT DETAILS

NDC Product Code69238-2548
Application NumberANDA211654
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJanuary 24, 2023
Generic NameTasimelteon

INGREDIENTS (9)

TASIMELTEONActive
Quantity: 20 mg in 1 1
Code: SHS4PU80D9
Classification: ACTIB
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
GELATINInactive
Code: 2G86QN327L
Classification: IACT
FD&C BLUE NO. 1Inactive
Code: H3R47K3TBD
Classification: IACT
FD&C RED NO. 40Inactive
Code: WZB9127XOA
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tasimelteon - FDA Drug Approval Details